Fierce Biotech August 22, 2024
After raising $213 million in 2023—one of the year’s largest private biotech rounds—Tome Biosciences is making cuts.
“Despite our clear scientific progress, investor sentiment has shifted dramatically across the gene editing space, particularly for preclinical companies,” a Tome spokesperson told Fierce Biotech in an emailed statement. “Given this, the company is operating at reduced capacity, maintaining core expertise, and we are in ongoing confidential conversations with multiple parties to explore strategic options.”
The company didn’t answer questions about how many, if any, employees will be affected by the changes. Furthermore, details about possible changes to Tome’s pipeline were not disclosed.
The gene editing biotech’s shrinkage was first reported by Stat. One person with knowledge of the situation told the publication...
Today's Sponsors
Today's Sponsor